IBM’s Quantum Leap Can’t Erase the $12.5 Billion Question Mark

IBM shares drop 25% in 2025 as $12.5B AI backlog is hidden, mainframe revenue declines, and quantum spending promises distant returns.

Investors in International Business Machines Corp. are being asked to swallow a bitter trade-off: trade the certainty of a $12.5 billion AI backlog for the promise of a quantum computing future. The market is not buying it — at least not yet.

Shares of the Armonk, New York-based technology giant have shed roughly a quarter of their value since the start of 2025, with the stock sliding 25.56 percent year-to-date to trade around €193.46. The sell-off accelerated in early July after second-quarter results revealed cracks in IBM’s most reliable profit engine — its mainframe business — and the company quietly stopped reporting the cumulative generative AI booking figure that had become the single most visible yardstick of its turnaround.

That number had reached $12.5 billion by the end of 2025, a tangible proof point that IBM’s bet on artificial intelligence was generating real revenue. By folding it into broader consulting and software metrics, management has effectively removed the one metric investors could point to and say: this transformation is working. What replaces it is a narrative about billions of dollars in quantum infrastructure spending — money that will be spent today for returns that may not materialize for years.

A Mainframe in Distress

The timing of that narrative shift could hardly be worse. IBM’s infrastructure division, anchored by the Z-series mainframe line, suffered a notable revenue decline in the second quarter. Management acknowledged it had been slow to adapt to shifting corporate IT budgets, as enterprise clients increasingly prioritize AI-ready hardware — specialized chips and high-performance servers — over traditional transaction-processing systems.

The company cut its full-year revenue forecast, confirming that the “deferred deals” flagged in July were not a one-off blip but part of a broader pattern of corporate spending restraint. The z17 cycle is struggling to match its predecessor’s performance, and IBM’s software business has yet to prove it can grow independently of the mainframe upgrade cycle that has historically provided a predictable revenue tailwind.

The market’s reaction was brutal. A single trading day in early July wiped out billions in market capitalization, and the stock has traded in turbulent territory ever since. Its 30-day volatility of 85.78 percent is far above what investors expect from a traditional blue chip. The shares currently sit about 10 percent above their 52-week low of €175.14, reached on July 23, but remain more than 34 percent below the June high of roughly €292.85.

Legal Clouds Gather

Compounding the operational headache is a growing legal overhang. Several prominent securities law firms have launched investigations into whether IBM misled investors about the pace of new business closures and the outlook for its Z product line. The probes add a layer of uncertainty that was not fully reflected in analyst price targets when they were set.

The consensus analyst target currently stands at €212.87, implying roughly 10 percent upside from current levels. A separate survey of analysts puts the average target at $215.43, suggesting an 11.1 percent potential gain. Both figures, however, were formulated before the full scope of the legal risks became apparent.

Quantum’s Distant Promise

On July 30, 2026, IBM announced what it called a breakthrough in “quantum advantage,” achieved alongside partners including Algorithmiq and Qedma. The company’s quantum systems solved materials-science problems that the world’s most powerful classical supercomputers could not crack. It was a genuine milestone, one that cements IBM’s position as a leader in the race to build commercially viable quantum computers.

But for investors nursing losses in a stock that has shed more than a third of its value from its 52-week high, the quantum narrative is a hard sell. The company is asking the market to judge it not on near-term AI bookings but on the potential of a technology that may not generate meaningful revenue for a decade. In a market that rewards immediate results, that is a difficult pitch — especially when the traditional mainframe business, long the company’s anchor, is itself adrift.

Cash Flow Keeps the Lights On

There are reasons for patience. IBM continues to generate enough free cash flow to fund its dividend and make strategic acquisitions. The announced purchase of HRL Laboratories, for instance, is designed to bolster quantum research capabilities. Value-oriented investors have begun to nibble, drawn by the stock’s depressed valuation and the company’s commitment to maintaining its cash-flow targets.

Yet the stock remains a high-risk bet on whether IBM can successfully navigate the transition from a mainframe-centric hardware company to a provider of AI software and quantum computing services. The gap between its current price and the 52-week high of €292.85 — a chasm of roughly 34 percent — illustrates just how much growth premium the market has already stripped away.

For individual investors, the calculus is straightforward but uncomfortable. IBM is no longer a safe harbor. It is a turnaround story that demands faith in a distant future, while the present is being shaped by a mainframe slowdown, a vanished transparency metric, and the specter of legal action. To hit analyst targets, the company must prove two things: that its software portfolio can grow without a mainframe tailwind, and that those deferred enterprise deals will close in the coming quarters. Until then, the stock remains a story that has yet to write its next chapter — in a market that has little patience for unfinished drafts.